纳米载体
介孔二氧化硅
动力学
化学
连接器
药物输送
纳米颗粒
纳米材料
生物物理学
组合化学
纳米技术
阿霉素
控制释放
介孔材料
A549电池
纳米囊
材料科学
有机化学
生物化学
体外
计算机科学
催化作用
外科
物理
操作系统
化疗
生物
医学
量子力学
作者
Andrea C. Ortiz,Nicolás Jackson,Neudo Buelvas,Alejandro Jerez,Rodrigo López‐Muñoz,Javier Morales,Francisco Arriagada
标识
DOI:10.1016/j.jddst.2023.105212
摘要
Silica-based stimuli-responsive nanomaterials have attracted significant attention in the field of drug delivery because they can achieve controlled release of anticancer drugs. For this, a gatekeeper is usually used, thus avoiding unwanted leakage at pH 7.4, while modulating the release under more acidic pH conditions in the tumor cell microenvironment. To optimize the efficiency of these nanostructures, it is crucial to study the release kinetics of anticancer drugs, predict their behavior, and modify the transport process mechanism. In the present study, we synthesized and characterized two types of pH-responsive mesoporous silica nanocarriers, which have transferrin conjugates on the surface serving as a gatekeeper. One nanocarrier was a conventional mesoporous silica nanoparticle (MSN) with transferrin attached through a pH-sensitive linker (MSN-Tf), while the other had a pH-sensitive diimine bridge in its framework, giving it degradable characteristic (dMSN-Tf). The use of conventional mathematical models and a three-parameter model that considers the drug-matrix interaction allowed the evaluation and elucidation of the different mechanisms involved in the kinetics of doxorubicin release from both materials at pH 7.4 and pH 5.0. The change in the kinetics of doxorubicin release from zero-order to first-order when it is in a degradable system such as dMSN-Tf, can be very useful for rapid drug delivery in acidic media such as inside cancer cells. Cell viability experiments in lung cancer cell lines A549 and H1299, showed enhanced anticancer activity by the nanomaterial with the pH-sensitive framework compared to the material that has a pH-sensitive linker. Overall, these findings provide important insights for optimizing the delivery of anticancer drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI